Multifactorial Approach to Predicting Resistance to Anthracyclines
PURPOSE: Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant TOP trial, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase IIα (TOP2A) and to develop a gene expression signature to identify those patients who do not benefit from anthracyclines. METHODS: The TOP trial included...
Provenance — who produced it, who reused it
Linked to 46 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Survival analysis across the entire transcriptome identifies bio... 2021 · 1,740 cites
- Aerobic glycolysis tunes YAP/TAZ transcriptional activity 2015 · 420 cites
- TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer 2012 · 303 cites
- Amplification and high-level expression of heat shock protein 90... 2012 · 183 cites
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and... 2012 · 181 cites
- EMT is associated with an epigenetic signature of ECM remodeling... 2019 · 148 cites
- HMGA1 promotes metastatic processes in basal-like breast cancer... 2013 · 134 cites
- The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to... 2019 · 92 cites
- Fatty acid receptor GPR120 promotes breast cancer chemoresistanc... 2019 · 72 cites
37 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently